Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCase Comprehensive Cancer Center
About this trial
The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
Eligibility criteria
Qualifiers
Antecedent hematological disease (e.g., myelodysplasia (MDS))
Treatment-related
Complete Remission (CR1) with poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, TP53 mutations, complex cytogenetics)
Participants must be in CR1, CR2, CR3 or CRi
Disqualifiers
Creatinine clearance < 40ml/min (Cockcroft-Gault)
Bilirubin > 2X institutional upper limit of normal unless Gilbert syndrome
AST (SGOT) > 3X institutional upper limit of normal
ALT (SGPT) > 3X institutional upper limit of normal
Trial design
Treatments tested in this trial
- Haplo-Identical / Cord Blood Transplant
Treatment groups
36 Participants
are divided into 1 treatment groupLocations
1Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center44106, ClevelandOhio, United States
Sponsors and collaborators
Case Comprehensive Cancer Center
Lead sponsor
Source ClinicalTrials.gov